IVA Inventiva SA

Inventiva to Participate in Upcoming September Investor Conferences

Inventiva to Participate in Upcoming September Investor Conferences

Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in the following upcoming investor events: 

H.C. Wainwright 27th Annual Global Investment Conference

Date: Tuesday, September 9, 2025

Time of the fireside chat: 3:00pm (EDT)/9:00pm (CEST)

Location: New York, NY

8th Edition of the Lyon Pôle Bourse Forum

Date: Tuesday, September 23, 2025

Location: Lyon, France

KBC Life Sciences Conference 

Date: Thursday, September 25, 2025

Time of the presentation: 5:00am (EDT)/11:00am (CEST)

Location: Brussels, Belgium

Stifel 2025 Virtual Cardiometabolic Forum

Date: Tuesday, September 30, 2025

Time of the presentation: 9:30am (EDT)/3:30pm (CEST)

Location: Virtual

European MIDCAP Event 2025

Date: Tuesday, September 30 - Wednesday, October 1, 2025

Location: Paris, France



  

About Inventiva



Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA).

Contacts 

Inventiva



Pascaline Clerc



EVP, Strategy and Corporate Affairs







   
ICR Healthcare



Alexis Feinberg



Media Relations













 





 
ICR Healthcare



Patricia L. Bank



Investor Relations



 



Attachment



EN
04/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Inventiva SA

 PRESS RELEASE

Inventiva to Participate in Upcoming September Investor Conferences

Inventiva to Participate in Upcoming September Investor Conferences Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in the following upcoming investor events:  H.C. Wainwright 27th Annual Global Investment ConferenceDate: Tuesday, September 9, 2025Time of the fi...

 PRESS RELEASE

Inventiva annonce sa participation à plusieurs conférences investisseu...

Inventiva annonce sa participation à plusieurs conférences investisseurs en septembre Daix (France), New York City (New York, Etats-Unis), le 4 septembre 2025 – (Euronext Paris et Nasdaq : ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que son équipe de direction participera aux conférences investisseurs suivantes :H.C. Wainwright 27th Annual Global Investment Conference Date : Mardi 9 septembre 2025Heur...

Guy Sips ... (+6)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Lewi

Morning Notes : AGS BB, AGFB BB, IVA FP, RET BB, TWEKA NA, VAN BB, NXF...

: AGS BB, AGFB BB, IVA FP, RET BB, TWEKA NA, VAN BB, NXFIL NA, IMCD NA

Jacob Mekhael
  • Jacob Mekhael

Inventiva A MASH turnaround story with big upside potential

Inventiva's lanifibranor is the next in line candidate in MASH, with its phase 3 (NATiV3) trial now fully recruited, locking in a topline readout for 2H26. The program is de-risked by a robust phase 2b, showing competitive fibrosis response rates and strong HbA1c reduction— a key differentiator for the large MASH + T2D population. With oral dosing and clean safety, lanifibranor is well-positioned to capture a meaningful share of the validated MASH commercial opportunity. A € 348m structured fina...

 PRESS RELEASE

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45t...

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference Daix (France), New York City (New York, United States), August 11, 2025 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that Jason Campagna, MD, PhD, President of R&D and Chief Medical Officer, and David Nikodem, PhD, Vice President of US Operations will participate in a fireside chat at the Canacc...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch